A late phase II study of S-1 for metastatic pancreatic cancer

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 615-621

  Okusaka, Takuji ^a   Funakoshi, Akihiro ^b   Furuse, Junji ^c   Boku, Narikazu ^d   Yamao, Kenji ^e   Ohkawa, Shinichi ^f   Saito, Hiroshi ^g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g Yamagata Prefectural Central Hospital   (Japan)

Author keywords

Chemotherapy; Pancreatic cancer; Phase II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; AMINOMETHYLTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; GAMMA GLUTAMYLTRANSPEPTIDASE BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; MALE; METASTASIS; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OXONIC ACID; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR;

EID: 38049048176     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0514-8     Document Type: Article

References (27)

1. Lowenfels AB, Maisonneuve P (2004) Epidemiology and prevention of pancreatic cancer. Jpn J Clin Oncol 34:238-244
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
3. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408
4. Moore MJ (2005) Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 32(6 Suppl 8):S5-S6
5. Cunningham D, Chau I, Stocken D, Davies C, Dunn J, Valle J et al (2005) Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 3:12
6. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
7. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N et al (2004) Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 100:2355-2361
8. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K et al (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83:141-145
9. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85:939-943
10. Furuse K, Kawahara M, Hasegawa K, Kudoh S, Takada M, Sugiura T et al (2001) Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 6:236-241
11. Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191-197
12. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y et al (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 57:202-210
13. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
14. Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B (2001) Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28:1381-1390
15. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S et al (2004) A phase II study of S-1 in patients with metastatic breast cancer-a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11:194-202
16. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T et al (1998) Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13:693-698
17. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68:171-178
18. Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101-130
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216
20. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
21. Kindler HL (2005) Front-line therapy of advanced pancreatic cancer. Semin Oncol 32(6 Suppl 9):S33-S36
22. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ et al (2006) Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 107:676-685
23. Ueno H, Okada S, Okusaka T, Ikeda M, Kuriyama H (2002) Phase II study of uracil-tegafur in patients with metastatic pancreatic cancer. Oncology 62:223-227
24. Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160-164
25. O'Neill VJ, Twelves CJ (2002) Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 87:933-937
26. Ueno H, Okusaka T, Ikeda M, Ishiguro Y, Morizane C, Matsubara J et al (2005) A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69:421-427
27. Nakamura K, Yamaguchi T, Ishihara T, Sudo K, Kato H, Saisho H (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575-1579